JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand

Gut

Volumn 58, Issue 5, 2009, Pages 688-698

  Mucha, S R ^a   Rizzani, A ^a   Gerbes, A L ^a   Camaj, P ^a   Thasler, W E ^a   Bruns, C J ^a   Eichhorst, S T ^a   Gallmeier, E ^a   Kolligs, F T ^a   Goke B ^a   De Toni, E N ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTHRA(1,9 CD)PYRAZOL 6(2H) ONE; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; APOPTOSIS REGULATORY PROTEIN; FAS ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSGENIC MOUSE; ANIMAL; APOPTOSIS; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTHRACENES; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL CYCLE; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 66349131044     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.154625     Document Type: Article

References (41)

1. El Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007:132:2557-76.
2. Eichhorst ST, Krammer PH. Derangement of apoptosis in cancer. Lancet 2001:358:345-6.
3. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-def cient mice. J Immunol 2002:168:1356- 61.
4. Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets 2005:9:83-99.
5. De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008:14:4713-8.
6. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008:118:1979-90.
7. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999:104:155-62.
8. Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006:12:2640-6.
9. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000:6:564-7.
10. Garber K. New apoptosis drugs face critical test. Nat Biotechnol 2005:23:409-11.
11. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007:25:1390-5.
12. Gajewski TF. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007:25:1305-7.
13. Armeanu S, Lauer UM, Smirnow I, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003:63:2369-72.
14. Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007:46:1498-508.
15. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999:5:157-63.
16. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2007;45:649-58.
17. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specifc apoptosis within a therapeutic window. JHepatol 2007;46:682-91.
18. De Toni EN, Kuntzen C, Gerbes AL, et al. P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes. JHepatol 2007:46:682-91.
19. Czaja MJ. The future of Gl and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 2003:284:G875-9.
20. Wang Y, Singh R, Lefkowitch JH, et al. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 2006:281:15258-67.
21. Sakurai T, Maeda S, Chang L, et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006:103:10544-51.
22. Schmidt CM, McKillop IH, Cahill PA, et al. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997:236:54-8.
23. Yuen MF, Wu PC, Lai VC, et al. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001:91:106-12.
24. Guo L, Guo Y, Xiao S, et al. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 2005:77:1869-78.
25. Kuntzen C, Sonuc N, De Toni EN, et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 2005:65:6780-8.
26. Thasler WE, Weiss TS, Schillhorn K, et al. Charitable State-Controlled Foundation Human Tissue and Cell Research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 2003:4:49-56.
27. Weiss TS, Pahernik S, Scheruebl I, et al. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol 2003:38:476-82.
28. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 1999:21:326-9.
29. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991:139:271-9.
30. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997:99:403- 13.
31. Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000:82:1211-7.
32. Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001:61:4942-6.
33. Ganten TM, Haas TL, Sykora J, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004:11 (Suppl 1):S86-S96.
34. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003:2:199-201.
35. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003:2:554-65.
36. Mundt B, Wirth T, Zender L, et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005:54:1590-6.
37. Mundt B, Kuhnel F, Zender L, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003:17:94-6.
38. Higuchi H, Grambihler A, Canbay A, et al. Bile acids up-regulate death receptor 5/ TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004:279:51- 60.
39. Malhi H, Barreyro FJ, Isomoto H, et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007:56:1124-31.
40. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wld-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995:15:3032-40.
41. Levine AJ. p53, the cellular gatekeeper for growth and dwision. Cell 1997:88:323-31.